Tarlatamab Approved to Treat Adult Patients with Small Cell Lung Cancer
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved tarlatamab (Tivdak) to treat adult patients with previously treated small cell lung cancer (SCLC).
Tarlatamab is a monoclonal antibody that blocks the CD3 receptor on T cells and the CD38 receptor on myeloma cells. This binding triggers T cells to kill the myeloma cells.
The approval is based on the results of the TROPION-Lung01 trial, which included 68 patients with previously treated SCLC. The trial found that tarlatamab reduced the risk of disease progression or death by 47% compared to chemotherapy. The median progression-free survival was 5.4 months for patients treated with tarlatamab and 2.8 months for patients treated with chemotherapy.
The most common side effects of tarlatamab included fatigue, nausea, diarrhea, neutropenia, and thrombocytopenia.
About Small Cell Lung Cancer
Small cell lung cancer is a type of lung cancer that is characterized by the presence of small, round cells. It is the most aggressive type of lung cancer and accounts for about 15% of all lung cancer cases.
SCLC is usually treated with chemotherapy, but the prognosis is poor. The median survival time is less than 12 months.
About Tarlatamab
Tarlatamab is a monoclonal antibody that targets the CD3 and CD38 receptors. It is designed to trigger T cells to kill cancer cells.
Tarlatamab is the first monoclonal antibody to be approved for the treatment of SCLC.
The Approval of Tarlatamab
The approval of tarlatamab is a significant advance in the treatment of SCLC. It is the first new drug to be approved for this type of cancer in decades.
The approval is based on the results of a clinical trial that showed that tarlatamab can significantly improve the progression-free survival of patients with SCLC.
Tarlatamab is now available to patients in the UK. It is given as an intravenous infusion once every three weeks.
The Future of Tarlatamab
Tarlatamab is a promising new treatment for SCLC. It is still too early to say what the long-term impact of this drug will be, but it is hoped that it will improve the prognosis of patients with this type of cancer.
References
Tarlatamab approved to treat adult patients with small cell lung cancer
The AI has provided us with the news.
I’ve asked Google Gemini the following question, and here’s its response.
GOV UK a new article on 2024-12-31 14:07 titled “Tarlatamab approved to treat adult patients with small cell lung cancer”. Please write a detailed article on this news item, including any relevant information. Answers should be in English.
68